ClinicalTrials.gg
CompletedNCT00688272Updated Nov 17, 2017

Study In Healthy Subjects To Evaluate The Photo-Irritant Potential Of Eltrombopag

A Phase 1 interventional study of Ciprofloxacin and Eltrombopag in Purpura, Thrombocytopaenic, Idiopathic, sponsored by GlaxoSmithKline. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-11-17.

Sponsored by GlaxoSmithKline · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing eltrombopag in Purpura — none open to participants now, none under way, none of them phase 3. eltrombopag · Purpura.

Enrollment
9th of 11
36 · median 82
Started
2008
the only one that year
Phase 1
4 of 11
none open now
Registered
7th of 11
by date
Lead sponsor
9 of 11
GlaxoSmithKline

Among the 11 studies testing eltrombopag in Purpura, this one is the 9th largest by enrollment, is the only one that started in 2008, is one of 4 in phase 1, and was the 7th registered.

Purpura

45 studies on the registry are indexed under Purpura; 4 are open to participants now.

Browse Purpura studies →

Open to participants now

None of the 11 studies testing eltrombopag in Purpura is open now. The open studies under Purpura, anywhere →

About eltrombopag

eltrombopag: first FDA approval 2008 (PROMACTA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 4 Purpura studies recruiting now, 2 set no upper age limit and 2 stop at 75 or younger; 1 takes children under 18; none take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies testing eltrombopag in Purpura as a file.
02

Study summary

This study is designed to investigate the safety profile and the photoirritant potential of eltrombopag in healthy subjects. The study is placebo- and positive controlled, randomized, parallel group with three treatment arms: eltrombopag (75 mg QD), placebo, and a positive control (ciprofloxacin, 500 mg BID). Eltrombopag will be administered in a double-blind fashion with respect to placebo and the positive control, ciprofloxacin, will be administered under observer-blinded conditions. Twelve to fifteen subjects will be recruited into each arm, to assure total enrollment of 36 evaluable subjects. The primary endpoint is the photosensitizing potential of eltrombopag as measured by photoirritant index (PI) and change in minimum erythemal dose (MED) in comparison with placebo.

03

Conditions studied

  • Purpura, Thrombocytopaenic, Idiopathic

Keywords

  • Safety
  • Photoirritant
  • Photosensitivity
  • Placebo control
  • Ciprofloxacin
  • Eltrombopag
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria:

  • Healthy Caucasian male or females with no abnormality identified by the physician by evaluation of medical history, physical examination, clinical laboratory tests or 12-lead .
  • Subjects were adult males or females between 18 and 65 years of age, inclusive.
  • All female subjects of child bearing potential agreed to commit to one of the protocol approved methods of , and that they were used consistently and in accordance with both the product label and the instructions of a physician. Female participants are not permitted to use Hormonal form of contraception (combined oral contraceptive pills etc) because of its known potential to induce photosensitivity.
  • All male subjects agreed to abstain completely from (or use a condom during) sexual intercourse with a pregnant or lactating female.
  • All male subjects with partner(s) who is /are able to have children agreed to use condom with spermicide from screening until 90 days after the last dose of study medication. In addition, their partner (s) had to also use one of the following forms of contraception until 90 days after last date of study medication:
  • Hormonal contraception i.e. the pill or hormones given by injection or given under the skin.
  • Diaphragm with spermicide
  • Cervical cap or female condoms.
  • An intrauterine device (a coil micro-insert).
  • Intrauterine system (IUS) e-g Mirena coil
  • Tubal ligation
  • Body weight greater than or equal to 50 kg and within the range 19-29.9 kg/m2.
  • A signed and dated written was obtained for the subject.
  • Skin Type 1, 2, or 3 according to the dermatological scale presented in the study protocol (see Modular Appendices).
  • Negative test for porphyrins, ANF, anti-Ro and anti-La (tests for lupus erythematosus) at screening.
  • Liver function tests (LFTs; , ALT, ALP, , gamma-GT) within the reference range, or deviations that were not considered clinically significant at screening by the investigator.
  • Subjects who had a normal value of MED in comparison with the normal population databank at the photobiology unit, Dundee.
  • The subject was able to understand and comply with protocol requirements and time tables, instructions and protocol-stated restrictions Exclusion Criteria
  • Any abnormality identified on the screening medical assessment that in the opinion of the investigator and GlaxoSmithKline medical monitor could have been associated with an increased rish to the subject or could have interfered with study procedures.
  • Subjects who had any sun or sunbed exposure to the skin of the back during the four weeks prior to the screening period.
  • Subjects with history of polymorphic light eruption.
  • Subjects who had a history of sensitivity to ciprofloxacin, any of the study medications or components thereof.
  • Subjects with history of malignant melanoma in a first degree family member.
  • Subjects with history of Gilbert Syndrome.
  • Subjects with history of deep vein thrombosis or any other thromboembolic event.
  • Subjects with history of sensitivity to heparin, or heparin-induced thrombocytopenia.
  • Subjects with history of clumping that prevents reliable measurement of platelet counts.
  • Subjects with history of thrombocytopenia or bleeding due to abnormal platelet number or function.
  • Subjects with C-reactive protein (CRP) that is elevated above normal range and considered clinically significant at screening.
  • Subjects with history of myocardial infarction, stroke or sudden unexplained death in a first degree family member under the age of 60 years.
  • Subjects with clotting factor abnormalities associated with hypercoagulability, specifically Factor V Leiden, Protein C, or Protein S deficiency, or antithrombin III deficiency.
  • Subjects with , white blood cells, platelet count or reticulocyte count that are outside the reference range and considered clinically significant at screening by the investigator.
  • Subjects with positive test for , virus or virus.
  • Subjects with positive urine drug screen including alcohol.
  • Subjects with history of alcohol/drug abuse or dependence within 12 months of screening.
  • History of regular alcohol consumption exceeding average weekly intake of greater than 21 units or an average daily intake of greater than three units (males) or an average weekly intake of greater than 14 units or an average daily intake of greater than two units (females). One unit is equivalent to a half-pint (220 mL) of beer/lager or one (25 mL) measure of spirits or one glass (125 mL) of wine.
  • Subjects who could not refrain from smoking during the study period from Day-1 through the completion of follow-up assessments.
  • Subjects who had received treatment with an drug within 30 days or five half-lives (whichever is longer) preceding the first dose of study medication.
  • Subjects who had been exposed to more than four new chemical entities within 12 months prior to the first dosing day.
  • Subjects who had taken any prescription or non-prescription drugs (including aspirin and NSAIDs), vitamins, herbal and dietary supplements, or any herbal remedies containing St. John's Wort within seven days (or 14 days if the drug is a potential enzyme inducer) or five half-lives (whichever is longer) prior to the first dose of study medication and through the completion of follow-up assessments. By exception, acetaminophen (or, paracetamol) at doses of less than or equal to 2 g/day and stable thyroid replacement therapy was allowed.
  • Consumption of antacids (e.g., Maalox, Mylanta, Amphogel, Milk of Magnesia or TUMS™) within 48 h of the first dose of study medication and until the completion of follow-up assessments.
  • Subjects who had an clinically significant skin/allergic disease, including photo-allergy (excluding non

    • active hay fever).
  • Subjects with multiple tattoos which may have obscured skin reactions or which restricted the skin surface area available for testing.
  • Subjects had to abstain from consumption of grapefruit, pomelo or Seville oranges from screening until the completion of follow-up assessments
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
Double (Participant, Investigator)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    Arm 1

    Eltrombopag 75 mg QD x 6 days

    Drug: Eltrombopag

  • Active comparator
    Arm 2

    Ciprofloxicin 500mg BID x 6 days

    Drug: Ciprofloxacin

  • Placebo comparator
    Arm 3

    Placebo QD x 6 days

    Drug: Placebo

Interventions

  • Given 500mg BID x 6 days

  • Given QD x 6 days

    Also known as: Ciprofloxacin

  • DrugPlacebo

    Given QD x 6 days

06

What researchers measure

Primary outcomes

  1. Evaluate the photosensitizing potential, as measured by photoirritant index and change from baseline in minimum erythemal dose, of eltrombopag when dosed orally at 75 mg QD as compared to placebo and ciprofloxacin 500 mg BID.

    Time frame: Screening - Day 8

Secondary outcomes

  1. Severity of phototoxic response Concentration of porphyrins, ANF, anti-Ro, and anti-La as measured on Day 6.

    Time frame: Day 6

  2. Vital signs (blood pressure, heart rate, respiration rate and body temperature) taken after resting semi-supine position for at least 10 minutes;

    Time frame: Screening, Days 1,2,3,4,5,6,7, and f/u

  3. Clinical laboratory tests

    Time frame: Screening, Day 1, 7 and f/u

  4. Assessment of AEs.

    Time frame: Continuous trhoughout the study.

07

Study locations

1 site
  • GSK Investigational Site
    Dundee, DD1 9SY, United Kingdom
08

References and documents

Publications

  • Bowen CJ, Lobb KM, Park JW, Sanderson B, Ferguson J. Eltrombopag (75 mg) does not induce photosensitivity: results of a clinical pharmacology trial. Photodermatol Photoimmunol Photomed. 2010 Oct;26(5):243-9. doi: 10.1111/j.1600-0781.2010.00538.x. PubMed 20831698 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2008 to primary completion in Sep 2008, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 28, 2008
First posted
Jun 2, 2008
StartActual
Jun 2, 2008
Primary completionActual
Sep 25, 2008
CompletionActual
Sep 25, 2008
Last update
Nov 17, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 17, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00688272
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Jun 2, 2008
Start date
Jun 2, 2008
Primary completion
Sep 25, 2008
Completion
Sep 25, 2008
Last update
Nov 17, 2017

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Eltrombopag

Start the discussion